[HTML][HTML] Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene therapy, 2020 - nature.com
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device-the …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - 2020 - pubmed.ncbi.nlm.nih.gov
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
[HTML][HTML] Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene …, 2020 - ncbi.nlm.nih.gov
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device–the …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene Therapy, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The SERCA-LVAD trial was a phase 2a trial
assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying the …
assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying the …
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device-the …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene …, 2020 - europepmc.org
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device-the …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene Therapy, 2020 - go.gale.com
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device-the …
AR Lyon, D Babalis, AC Morley-Smith, M Hedger… - Gene …, 2020 - europepmc.org
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …
an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum …